Adaptive Blood Purification for the Treatment of Patients With Septic Shock

Official title

Adaptive Blood Purification for the Treatment of Patients With Septic Shock: a Multicenter, Open-label, Randomized, Parallel Controlled Study

Overview

There is a lack of evidence in the efficacy of extracorporeal blood purification (EBP) to reduce the mortality rate in septic shock. We have designed the EABPSS (Efficacy of Adaptive Blood Purification for Septic Shock) study to confirm whether adaptive blood purification (ABP) intervention could confer a clinical benefit. In this multicenter, open-label, randomized controlled trial, We are recruiting a total of 276 patients with septic shock. Eligible patients who provide informed consent will be randomly assigned in a 1:1 ratio to either the control group or the intervention group. Patients in the control group will receive standard care according to the Surviving Sepsis Guidelines. Patients in the intervention group will receive two 6-hour sessions of ABP treatment within 24 hours of enrollment, based on standard care. ABP is a novel, adaptive EBP strategy proposed by our research team, specifically, for patients with septic shock do not require renal replacement therapy (RRT), plasma filtration-adsorption (PFAD) will be used alone, and for patients with septic shock and acute kidney injury meeting RRT indications, a combination of PFAD-RRT will be employed. The primary endpoint of this study is all-cause mortality at 90 days after enrollment. Secondary endpoints of the study include the declining proportion of serum cytokines such as TNF-α, IL-4, IL-6, IL-8, IL-10, and HMGB1 within 24 hours after enrollment. Additionally, the study will evaluate the improvement of Sequential Organ Failure Assessment score on day 7 post-enrollment, as well as the 30-day mortality rate.

Interventions

• Other Adaptive Blood Purification (ABP)
  Patients in the intervention group, based on standard treatment, received two 6-hour adaptive blood purification (ABP) treatments within 24 hours after enrollment, that is, patients did not indicate renal replacement therapy (RRT), only coupled plasma filtration-adsorption (PFAD) therapy is used to adsorb inflammatory factors; for patients with acute kidney injury (AKI) and meeting RRT indications, PFAD-RRT treatment is used.

Primary outcome measures

• All-cause mortality at day 90 [Time frame: The follow-up time ends on the 90th day after patient enrollment.]

Secondary outcome measures (6)

• Declining proportion of serum cytokines [Time frame: From enrollment to the end of first 24 hours.]
• Improvement of SOFA score [Time frame: The follow-up time ends on the 7th day after patient enrollment.]
• All-cause mortality at day 30 [Time frame: The follow-up time ends on the 30th day after patient enrollment.]
• Duration of stay [Time frame: The follow-up time ends on the 90th day after patient enrollment.]
• Mortality rate [Time frame: The follow-up time ends on the 90th day after patient enrollment.]
• Requirement of RRT [Time frame: The follow-up time ends on the 90th day after patient enrollment.]

Eligibility criteria

Inclusion criteria

• Adult patients admitted to intensive care unit (ICU), 18 years old ≤ age ≤ 82 years old;
• Meeting the diagnostic criteria for septic shock (Sepsis 3.0), and the onset time of septic shock ≤ 24 hours;
• Systemic inflammatory response syndrome (SIRS) ≥ 3 points;
• Sequential organ failure assessment (SOFA) ≥ 6 points;
• Voluntarily sign the informed consent form before the trial, and agree to participate in all visits, examinations, and treatments according to the requirements of the research plan.

Exclusion criteria

• Patients who have received blood purification treatment within 1 week for any reason;
• Patients with congenital or acquired immunodeficiency diseases, or those who have received organ transplantation;
• Patients who have received immunosuppressive drugs (mycophenolate, cyclophosphamide, FK506, etc.) within 28 days before enrollment;
• Patients who received continuous treatment (≥ 3 days) with more than 10 mg/day of prednisolone (or other hormones at equivalent doses) within 28 days before enrollment;
• Patients with active bleeding (requiring blood transfusion > 3 units in the past 24 hours);
• Patients with malignant tumors, those who cannot remove the lesions (such as surgical patients who cannot undergo surgical treatment);
• End-stage organ failure (end-stage pulmonary heart disease, brain death, chronic liver disease combined with hepatic encephalopathy);
• Platelet count < 30×10\^9/L or neutrophil count < 0.5×10\^9/L;
• Patients who require supportive treatment due to acute pulmonary embolism or severe congestive heart failure;
• The mean arterial blood pressure (MAP) cannot be maintained ≥ 65 mmHg after receiving vasoactive drugs and fluid resuscitation treatment;
• Patients who have participated or participated in another clinical study within 28 days before enrollment;
• Patients who are allergic to extracorporeal circulation materials, perfusion device materials or have a history of other severe allergies, or those who have heparin-associated thrombocytopenia;
• Patients who are inappropriate for participating, such as pregnant or lactating women, patients with severe mental and neurological diseases, and those with a history of alcoholism that cannot be terminated.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Beijing Chao Yang Hospital — Beijing

Publications

• Jia H, Li X, Zheng Y, Cui N, Ronco C, Li W. Efficacy of Adaptive Blood Purification for Septic Shock (EABPSS): protocol for a randomised, multicentre, parallel controlled study. BMJ Open. 2025 Oct 20;15(10):e107311. doi: 10.1136/bmjopen-2025-107311. PMID 41120165

Identifiers

NCT: NCT06692036 · Capital'sFunds2024-1-2031

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗